Test Price
2,800 AED✅ Home Collection Available
RDX Gene Deafness (Autosomal Recessive Type 24) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary – Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM to 11 PM).
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The RDX Gene NGS Test screens for pathogenic variants in the RDX gene associated with autosomal recessive non-syndromic hearing loss type 24 (DFNB24). This comprehensive next-generation sequencing assay analyzes the entire coding region with high coverage, delivering diagnosis clarity for families. In the UAE, our DHA-licensed facility ensures result accuracy and genetic counselling support.
| Feature | Our NGS Test | Closest Alternative |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) with full gene coverage & bioinformatics | Sanger sequencing of selected RDX exons; may miss deep intronic variants |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Detection Rate | >99% for point mutations, small indels, and splice site variants | Variable; limited to targeted regions |
| Cost | 2800 AED (all-inclusive) | Quoted separately; often excludes counselling |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh (DHA: 9294403)
"As a Consultant Medical Genetics, I understand that hearing loss can be deeply concerning for families. This test is a powerful tool to uncover the genetic cause, but results must be correlated with detailed audiometric and clinical findings. Please remember, a negative result does not rule out other genetic or non-genetic causes; always consult your specialist."
Clinical Advisory
Genetic testing for hearing loss does not replace complete audiological evaluation. Results may require confirmation with additional biochemical or imaging studies. Discuss implications for family members and reproductive planning with your genetic counsellor.
Exclusion Criteria & Safety
- Exclusion Criteria: None for the genetic test itself; however, inform the phlebotomist if you have a bleeding disorder or are on high-dose anticoagulants. An alternative specimen type (buccal swab) may be recommended.
- Emergency Red Flags: Genetic testing for deafness does not carry immediate medical risks. If you experience sudden hearing loss or acute dizziness, seek emergency care independently of this test.
- Paediatric Use: For minors, testing requires consent from a legal guardian and a referral from a DHA-licensed specialist. All paediatric data handling complies with UAE PDPL and Federal Law No. 2 of 2019.
Patient FAQ & Clinical Guidance
1. What is the purpose of the RDX gene deafness NGS test?
This sequences the RDX gene to identify mutations causing autosomal recessive deafness type 24, enabling precise genetic diagnosis and informed family planning. Results help guide medical management and recurrence risk counselling.
2. How is the sample collected and what preparation is needed?
A blood sample or buccal swab is collected at home by our DHA-licensed phlebotomist using VIP Mobile Phlebotomy service. No fasting is required; please inform us of any medications you are taking.
3. How long does it take to receive results and what does the report include?
Results are delivered in 3 to 4 weeks with a comprehensive clinical report including variant interpretation, classification per ACMG guidelines, and genetic counselling recommendations.
UAE Regulatory & Data Privacy Adherence
Data Protection & Compliance
All genetic data is handled in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent is obtained prior to testing, and results are shared only with authorised clinicians and patients. The laboratory is DHA-licensed (Facility No. 1143) and accredited to ISO 9001:2015.
Clinical & Logistical Metadata
| Test Name | RDX Gene Deafness (Autosomal Recessive Type 24) Genetic Test (NGS) |
| Price (AED) | 2800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Buccal Swab (DNA) |
| Methodology Used | Next-Generation Sequencing (NGS) – Whole Gene Coverage + Bioinformatics Analysis |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 21659-6 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians